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hormone. Now there is ample evidence that low levels of
Vitamin D has been found to be associated with diabetes,
systemic hypertension, metabolic syndrome, coronary heart
disease (CHD), heart failure and vascular inflammation.1
In this issue of IHJ, Ambuj Roy et al2 report a study on the
independent association of vitamin D deficiency with coro-
nary heart disease.
1. Vitamin D e the basics
There are 2 major forms of vitamin D, vitamin D2 (ergo-
calciferol) and vitamin D3 (cholecalciferol). Vitamin D2 is
contained in plants and Vitamin D3 can be obtained through
conversion of 7-dehydrocholesterol in the human skin upon
exposure to ultraviolet B (UVB) radiation.
The Vitamin D is converted to 25(OH)D by liver, which is
converted to 1,25 (OH)2D (calcitriol) mainly by the kidney.
Although 1,25(OH)2D is considered to be the active form of
vitaminD, its levels in the serumdo not correlatewith the true
vitamin D status, whereas 25(OH)D (calcidiol) level is found to
be a more clinically relevant estimate.
The optimal levels of 25(OH)D vary based on different rec-
ommendations, but it has been suggested that the most ad-
vantageous serumconcentrationsof 25(OH)Dbeginat 30ng/mL
(75 nmol/L).3 Severe deficiency have beendefined as<10 ng/ml.
2. The association between Vitamin D levels
and cardiovascular disease
The association of low levels of vitamin D and CVD have been
proven in epidemiological cohort studies in Europe and the* Corresponding author.
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studies from Europe and the United States, lower serum
25(OH)D concentration was associated with increased all-
cause and cardiovascular mortality in subjects without pre-
existing cardiovascular diseases with a risk ratio of 1.41 (CI
1.18e1.68).4 It was found that a curvilinear relationship exists
between the serum concentrations of 25(OH)D and cardio-
vascular disease mortality. However, some authors have re-
ported a possible ‘J’ or ‘U’ shaped association with higher
cancer and cardiovascular disease risk both at low and high
serum concentrations of vitamin D.5
The mechanism of Vitamin D deficiency leading to athero-
sclerotic vascular disease is complex. It involves raised para-
thormone levels leading toheightenedRAAS (renin-angiotensin-
aldosterone) activity, insulin resistance and inflammation.
(Fig. 1). At the cellular level, vitaminDacts through the vitaminD
receptor (VDR), which is found in virtually all tissues of the body
including cardiovascular tissues like cardiomyocytes, endothe-
lial, and vascular smoothmuscle cells. Cardiovascular effects of
vitaminD share the common initial steps of nuclear and plasma
membrane VDR activation in the above cells. (Fig. 2).
There are few reports of association of CHD and vitamin D
levels from India. An observational study of hospitalized pa-
tients with AMI from Bengaluru reported 83.5% prevalence of
Vitamin D deficiency.6 The association between low vitamin D
levels and cardiovascular risk factors have also been noted in
previous studies from India.7
This study by Ambuj Roy et al2 is the first reported case
control study regarding the association of CHD with low
Vitamin D levels from India.
In this caseecontrol study the authors compared 120
consecutive cases of first incident acute myocardial infarction
(MI) and 120 age and gender matched healthy controls.reserved.
Fig. 1 e Themechanisms of Vitamin D deficiency leading to
atherosclerotic vascular disease. (PTH e parathyroid
hormone, RAAS e renin angiotensin aldosterone system,
HTN e hypertension, CVD e cardiovascular disease, LVH e
left ventricular hypertrophy).
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 1 1e1 312Vitamin D deficiency, as defined by the most widely used
criteria [25(OH) D < 30 ng/ml] was highly prevalent in cases
and controls (98.3% and 95.8% respectively) with median
levels significantly lower in cases (6 ng/ml and 11.1 ng/ml
respectively). Severe vitamin D deficiency [25(OH) D < 10 ng/
ml] conferred a significant a risk of MI compared to controls.
(odds ratio 4.5, CI 2.2e9.2).Fig. 2 e Mechanisms by which vitamin D deficiency may
confer cardiovascular risk. Potential effects of vitamin D
metabolism on the cardiovascular system are divergent,
but share common initial steps of nuclear and plasma
membrane VDR activation. VDR, vitamin D receptor; 1, 25-
OH D2, 1, 25-dihydroxyvitamin D; RXR, retinoid-X receptor;
Caþ, calcium cation; ANP, atrial natriuretic peptide; MMP,
matrix metalloproteinases; VDRE, vitamin D response
elements (promoter region of target genes); RAS,
renineangiotensin system; VEGF, vascular endothelial
growth factor; VSMC, vascular smooth muscle cells.
(Published with permission from EHJ, Ibhar Al Mheid et al.
Vitamin D and cardiovascular disease: is the evidence
solid? Eur Heart J. 2013 Dec;34(48):3691e8).A few points need to be discussed at this juncture.
1. High prevalence of Vitamin D deficiency in the general
population in India.
2. Vitamin D deficiency e is it a cause or an association?
3. Will supplementation of Vitamin D improve the outcomes
or can it harm?
Studies across India undertaken in diverse populations and
geographical locations emphasize the universal prevalence of
Vitamin D deficiency in the country to the tune of 70e100%.8
These studies have defined Vitamin D deficiency as serum
25(OH)D levels below 20 ng/mL or 30 ng/mL.
Even in this study by Roy et al,2 the prevalence of severe
Vitamin D deficiency as defined as levels <10 ng/mL was high
even in controls and only 4.2% of the controls had ‘sufficient’
Vitamin D levels. It is surprising that India which has abun-
dant sunshine and those majority in the rural areas involved
in the agricultural sector who are exposed to the sun have low
vitamin D levels. One factor proposed as a predisposing factor
in Indians is the low dietary calcium intake. Darker skin acts
as a ‘natural sunscreen’ too.
Thealternativeway to look at relation ofVitaminDandCHD
is to look into the evidence from supplementation studies. In
the west, fortification of milk and other food products with
either D3 or D2 is practiced and in some countries, it is
mandatory. However, in India, this is not prevalent. Due to
higher melanin content of the skin, minimum daily 45 min of
direct sunlight exposure is recommended to obtain adequate
Vitamin D in Indians. Supplementation is usually practised for
metabolic bone disease. A daily dose of not exceeding 4000 IU
(D3) is a common mode of supplementation. The weekly
60,000 IU (D3) regimewith calciumfor 8weeksdoesnot result in
sustained improvement of Vitamin D levels8 in the long term.
Even though the evidence for association of low 25(OH)D
levels with CHD is robust in both clinical and community level
settings, supplementation of Vitamin D with or without cal-
cium in diet does not seem to readily translate into improve-
ment of cardiovascular disease morbidity or mortality
independently as we discuss below.
A recent systematic review of 40 randomized control trials
concluded that Vitamin D supplementation [in ergocalciferol
(D2) or cholecalciferol (D3) form) to raise the serum 25(OH) D2
concentrations beyond 50 ng/ml did not reduce the relative
risk of CHD in community dwellers by more than 15%.9 In
another systematic review by Choudhury et al involving 22
studies (comprising of community level studies and clinical
registers, average ages ranging from 56 to 85 years) and 30716
subjects, supplementing VitaminD3 (and not D2)was found to
result in a modest 11% relative risk reduction for all-cause
mortality (risk ratio 0.89, CI 0.8e0.99).10 No impact on
Vitamin D supplementation has been found in the control of
hypertension in the recently published DAYLIGHT trial.11
There is paucity of data regarding the role of Vitamin D sup-
plementation in secondary prevention of CHD. There are even
studies reporting harmat higher serum levels of VitaminD.5,12
The actual reason for the difference in observations be-
tween association studies versus supplementation trials is not
fully understood. This could be due to the possibility of low
Vitamin D levels being an indicator of frailty and general ill-
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bacco use, insulin resistance, chronic diseases, inflammatory
conditions, malignancies etc. Rather than being the cause of
these conditions, it might indicate an effect on its own.
Secondly it could be the result of the cut-off levels used for
definition. The value of 30 ng/mL was derived based on the
relationship between serum PTH and 25(OH)D levels which
demonstrate a plateau in suppression of PTHwhen the 25(OH)
D level reaches approximately 30 ng/mL.3 Thismight not be an
optimal cut-off for the non-skeletal effects of the hormone, as
evidenced by severe ‘deficiency’ in both cases and controls.
We do not have normal levels specifically derived from the
Indian population.
Another parameter which could influence the functional
status of the hormone is the degree of protein binding and the
concentration of the active hormone. There could be multiple
confounding variables between a measured serum level and
hormonal effect. Finally, the impact of an intermediate term
supplementation of D2 or D3 with no consensus on the dose
on a chronic disease process like CHDmight not be significant.
The VITAL study is an ongoing research study in 25,875
men and women across the U.S. investigating whether taking
daily dietary supplements of vitamin D3 (2000 IU) or omega-3
fatty acids (1 g) reduces the risk for developing cancer, heart
disease, and stroke in people who do not have a prior history
of these illnesses. This study is expected to provide a definite
answer regarding the role of Vitamin D supplementation.3. Perspectives from the current study
The study poses more questions for the researchers regarding
the pathogenesis of atherosclerotic vascular disease. The as-
sociation needs to be established by longitudinal studies with
an objective to assess the impact if any on young age escala-
tion of CHD in India. Such information could help in adoption
of various life-style and dietary practices to improve vitaminD
activity from an early age as an attempt to tackle the tsunami
of CVD facing the country currently.r e f e r e n c e s
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